Trial Profile
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2020
Price :
$35
*
At a glance
- Drugs BMS 986020 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 20 May 2020 Results of evaluation of collagen neoepitope biomarkers in a phase 2 trial of BMS-986020 has been presented at the 116th International Conference of the American Thoracic Society
- 07 Sep 2018 Results published in the Chest.
- 29 Aug 2018 Primary endpoint (Rate of change in forced vital capacity (FVC)) has not been met, according to results published in the Chest.